← Back to Search

Other

PENG vs FIC Nerve Blocks for Hip Fracture Pain

N/A
Recruiting
Led By Lawrence Haines, MD
Research Sponsored by Antonios Likourezos
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Isolated hip fracture, intertrocanteric or more proximal
Pain score 5 or greater on a scale of 0 to 10 just prior to nerve block placement
Must not have
People who are unable to communicate their level of pain
Patients on long term systemic opioid analgesia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 minutes post administration of nerve block
Awards & highlights
No Placebo-Only Group

Summary

This trial will help to determine if the PENG block is non-inferior to the FIC block for pain control in patients with hip fractures.

Who is the study for?
This trial is for adults over 18 with an isolated hip fracture and a pain score of 5 or more. It's not for those with multiple injuries, communication issues about pain, pregnancy, under 18 years old, intoxication, abnormal vital signs, long-term opioid use or allergy to certain local anesthetics.
What is being tested?
The study compares two types of nerve blocks in emergency department patients with hip fractures: PENG block using Bupivacaine (0.50%) and FIC block using Bupivacaine (0.25%). The goal is to see if PENG provides similar or better pain relief than FIC without opioids.
What are the potential side effects?
Possible side effects include reactions at the injection site like numbness or discomfort; rare but serious risks involve nerve damage or systemic effects from the medication such as heart problems or allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have a hip fracture near the top of my thigh bone.
Select...
My pain level is 5 or higher on a scale of 0 to 10 before getting a nerve block.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot express how much pain I am in.
Select...
I am on long-term pain medication.
Select...
I am under 18 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 minutes post administration of nerve block
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 minutes post administration of nerve block for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Pain Score at 30 Minutes
Secondary study objectives
Pain Score at 60 minutes

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: PENG BlockActive Control1 Intervention
Pericapsular Nerve Group (PENG) Block (20mL of Bupivacaine 0.50%)
Group II: Fascia Iliaca CompartmentActive Control1 Intervention
Fascial Iliaca block (FIC) (40mL of Bupivacaine 0.25%) for patients with hip fractures in the ED

Find a Location

Who is running the clinical trial?

Antonios LikourezosLead Sponsor
40 Previous Clinical Trials
8,554 Total Patients Enrolled
17 Trials studying Pain
1,141 Patients Enrolled for Pain
Lawrence Haines, MDPrincipal InvestigatorMaimonides Medical Center

Media Library

FIC Proceedure (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05102760 — N/A
Pain Research Study Groups: PENG Block, Fascia Iliaca Compartment
Pain Clinical Trial 2023: FIC Proceedure Highlights & Side Effects. Trial Name: NCT05102760 — N/A
FIC Proceedure (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05102760 — N/A
~13 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top